Fidelity Management & Research Co has recently announced that it has increased stake in BioXcel Therapeutics Inc. (NASDAQ:BTAI) by 0.01%. After grabbing 4.2 million shares, the institutional investor is now in possession of 269.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 14.98% having worth around $69.55 million. Moreover, BlackRock Fund Advisors increased its share by 26818.0 to have a control over 1.26 million shares. And The Vanguard Group, Inc. raised its holdings to 34633.0 shares by acquiring 1.0 million shares or 3.58% of the stake.
BioXcel Therapeutics Inc. (BTAI) concluded trading on 01/11/23 at a closing price of $24.82, with 0.49 million shares of worth about $12.13 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.74% during that period and on Wednesday the price saw a gain of about 4.90%. Currently the company’s common shares owned by public are about 28.02M shares, out of which, 18.99M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the BTAI stock and their offered price forecasts bring an average price target of $41.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $76.00 and could fall to a lowest price of $16.00. The stock’s current price level is 47.9% above of average price target set by the analysts, while a rise to estimated low would result in loss of -55.12% for the stock. However, touching the estimated high of $76.00 would mean a gain of 67.34% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 60,000 shares in 2 of the transactions. In 2 selling transactions, insiders dumped 60,000 shares.
Fidelity Growth Company Fund, DNCA Invest – Beyond Global Leade, and Vanguard Total Stock Market Index are the top 3 mutual funds which are holding stakes in BioXcel Therapeutics Inc. Fidelity Growth Company Fund is currently holding 1.35 million shares of worth totaling $22.33 million. The company recently came selling 32129.0 shares which brought its stake up to 4.81% of the company’s outstanding shares. Vanguard Total Stock Market Index, after buying 0.65 million shares, have now control over 2.30% of the stake in the company. It holds 0.0 shares of worth $10.69 million.
BioXcel Therapeutics Inc. (NASDAQ: BTAI) started trading at $23.78, above $0.12 from concluding price of the previous day. However, the stock later moved at a day high price of 24.88, or with a gain of 4.90%. Stock saw a price change of 11.40% in past 5 days and over the past one month there was a price change of 45.83%. Year-to-date (YTD), BTAI shares are showing a performance of 15.55% which increased to 25.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.80 but also hit the highest price of $24.57 during that period. The average intraday trading volume for BioXcel Therapeutics Inc. shares is 257.06K. The stock is currently trading 17.81% above its 20-day simple moving average (SMA20), while that difference is up 42.16% for SMA50 and it goes to 69.00% higher than SMA200.
Fidelity Management & Research Co acquired 4.2 million shares of BioXcel Therapeutics Inc. having value of about $69.55 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 269.0 shares in the company valued at close to $6676.58, or have control over 0.01% stake in the company. BioXcel Therapeutics Inc. (NASDAQ: BTAI) currently have 28.02M outstanding shares and institutions hold larger chunk of about 47.90% of that. Holding of mutual funds in the company is about 30.41% while other institutional holders and individual stake holders have control over 32.17% and 16.68% of the stake respectively.
The stock has a current market capitalization of $687.27M and its 3Y-monthly beta is at 1.15. It has posted earnings per share of -$4.90 in the same period. It has Quick Ratio of 10.30 while making debt-to-equity ratio of 0.72. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BTAI, volatility over the week remained 6.34% while standing at 6.76% over the month.
Analysts are in expectations that BioXcel Therapeutics Inc. (BTAI) stock would likely to be making an EPS of -$1.35 in the current quarter, while forecast for next quarter EPS is -$1.32 and it is -$4.96 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.5 which is -$1.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.96 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -7.00% while it is estimated to decrease by -0.40% in next year.
Analysts at 9 brokerage firms have issued recommendations for the BioXcel Therapeutics Inc. (BTAI)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 9 Wall Street analysts, 8 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on December 01, 2022 offering a Neutral rating for the stock and assigned a target price of $16 to it. Coverage by Mizuho stated BioXcel Therapeutics Inc. (BTAI) stock as a Buy in their note to investors on July 07, 2022, suggesting a price target of $19 for the stock. On April 06, 2022, BofA Securities Reiterated their recommendations, while on November 15, 2021, Goldman Downgrade their ratings for the stock with a price target of $24. Stock get a Buy rating from Berenberg on April 09, 2021.